Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Johannet
Dr. Paul Johannet is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Veterans Affairs New York Harbor Healthcare System. He received his medical degree from Stanford University School of Medicine and has been in practice 9 years. He is one of 37 doctors at Veterans Affairs New York Harbor Healthcare System and one of 527 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 30 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2021
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Gastroenterology, 2019 - 2025
NYU Grossman School of MedicineResidency, Internal Medicine, 2018 - 2021
Stanford University School of MedicineClass of 2017
Certifications & Licensure
FL State Medical License 2024 - Present
NJ State Medical License 2024 - 2027
NY State Medical License 2020 - 2027
PA State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer.Matthew L Flint, Anna Shvygin, Paul Johannet, Seth Cohen, Jason Konner
International Journal of Gynecological Cancer. 2026-07-01 - Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.Lucy Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, Anna Jaeger, Linn Woelber
JAMA Oncology. 2026-06-25 - 11 citationsTherapeutic targeting of mismatch repair-deficient cancers.Paul Johannet, Benoit Rousseau, Carol Aghajanian, Michael B Foote, Luis A Diaz Jr
Nature Reviews. Clinical Oncology. 2025-10-01
Press Mentions
Promising Clinical Trial Predicts Cancer Risk and Recurrence in Patients Treated with ImmunotherapySeptember 15th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:





